In his latest message, Dr. Gordon discusses the role of NIMH and other researchers in the development of esketamine, an FDA-approved, rapid-acting medication that targets treatment-resistant depression.
from NIMH News Feed https://ift.tt/2YMq4Wu
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment